InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
61,010.78
(
1.16%
)
Post# of 10489
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

MDMSCF

Send PM Follow Ignore
Followers 0
Posts 37
Boards Moderated 0
Alias Born 10/16/2013

MDMSCF

Re: stockweiser post# 6090

Saturday, 01/10/2015 5:49:49 PM

Saturday, January 10, 2015 5:49:49 PM

Post# of 10489
From my understanding the way the trial is set up, the interim analysis will only be looking at safety and futility. Which means the only public statement released will be to continue the trial or stop the trial due to safety and/or futility. This does not mean the data for efficacy isn't reviewed, it is!
However, I'm hoping the data at the interim analysis is overwhelming enough that regulators consider it unethical to prevent this set of BC patients from receiving NeuVax.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up